The Basque Government is engaged in the international project to make this production possible in the Basque Country
Tapia highlights that, once Harvard advances with the vaccine, the Basque Country is ready to take on this opportunity that represents a unique health, social and business advance
Viralgen Vector Core is a partnership uniquely positioned in the CDMO industry to bring forward a robust suspension platform for AAV production in a facility custom-designed to bring therapies to market as quickly as possible. Viralgen is able to support every aspect of your AAV program from start to finish, including large-scale manufacturing, fill-finish, and quality control in a GMP-certified environment in San Sebastian, Basque Country.
Harvard has chosen Viralgen Vector Core as it becomes the convergence point from experienced specialized organizations in biotechnology and life sciences, united with the aim of creating a CDMO in the cutting-edge sector of gene therapy and innovative medicines. Devoted to the Development and Manufacturing of viral vectors, in order to contribute to the progress in health and welfare of people.
Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology...Read moreShare
Next January the Participants will be announced and the acceleration program will begin. 20 of...Read moreShare
La industria vasca prevé una afección global a corto-largo plazo imposible aún de cuantificar,...Read moreShare
AseBio brings together more than 730 companies that employ almost 100,000 people and invest more...Read moreShare
VIVEbiotech has carried out a capital increase of 3.5 million euros to finance its...Read moreShare
For SMEs, for diversifying markets, internships abroad, international tenders, non-reimbursable subsidies to consolidate exports, subsidies for deployments or specific training in internationalisation.You’re interested, right?